William Pickering
Stock Analyst at Bernstein
(3.48)
# 2,338
Out of 4,703 analysts
217
Total ratings
61.9%
Success rate
5.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by William Pickering
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $572 → $608 | $556.75 | +9.21% | 31 | Aug 11, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Rated: Hold | $35 → $46 | $85.37 | -46.12% | 9 | May 13, 2026 | |
| NTLA Intellia Therapeutics | Rated: Hold | $13 → $17 | $12.76 | +33.23% | 14 | May 13, 2026 | |
| CRSP CRISPR Therapeutics AG | Rated: Hold | $50 → $56 | $56.92 | -1.62% | 9 | May 13, 2026 | |
| BEAM Beam Therapeutics | Rated: Buy | $40 → $39 | $29.29 | +33.15% | 18 | May 13, 2026 | |
| DYN Dyne Therapeutics | Rated: Hold | $23 → $24 | $25.14 | -4.53% | 7 | May 13, 2026 | |
| BBIO BridgeBio Pharma | Reiterated: Buy | $100 → $114 | $76.50 | +49.02% | 4 | May 8, 2026 | |
| BMRN BioMarin Pharmaceutical | Rated: Buy | $94 → $82 | $66.97 | +22.44% | 21 | May 5, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $451 → $447 | $267.40 | +67.17% | 20 | May 1, 2026 | |
| ALLO Allogene Therapeutics | Maintained: Hold | $3.85 | $1.98 | +94.44% | 8 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $916 → $921 | $852.03 | +8.09% | 25 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $20 | $23.21 | -13.83% | 5 | Mar 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $28 | $39.49 | -29.10% | 1 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $35 | $34.18 | +2.40% | 1 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $157 → $201 | $222.67 | -9.73% | 10 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $65 → $89 | $61.33 | +45.12% | 22 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $34 → $9 | $15.69 | -42.64% | 12 | Nov 6, 2025 |
Vertex Pharmaceuticals
Aug 11, 2026
Maintained: Buy
Price Target: $572 → $608
Current: $556.75
Upside: +9.21%
Arrowhead Pharmaceuticals
May 13, 2026
Rated: Hold
Price Target: $35 → $46
Current: $85.37
Upside: -46.12%
Intellia Therapeutics
May 13, 2026
Rated: Hold
Price Target: $13 → $17
Current: $12.76
Upside: +33.23%
CRISPR Therapeutics AG
May 13, 2026
Rated: Hold
Price Target: $50 → $56
Current: $56.92
Upside: -1.62%
Beam Therapeutics
May 13, 2026
Rated: Buy
Price Target: $40 → $39
Current: $29.29
Upside: +33.15%
Dyne Therapeutics
May 13, 2026
Rated: Hold
Price Target: $23 → $24
Current: $25.14
Upside: -4.53%
BridgeBio Pharma
May 8, 2026
Reiterated: Buy
Price Target: $100 → $114
Current: $76.50
Upside: +49.02%
BioMarin Pharmaceutical
May 5, 2026
Rated: Buy
Price Target: $94 → $82
Current: $66.97
Upside: +22.44%
Alnylam Pharmaceuticals
May 1, 2026
Reiterated: Buy
Price Target: $451 → $447
Current: $267.40
Upside: +67.17%
Allogene Therapeutics
Apr 14, 2026
Maintained: Hold
Price Target: $3.85
Current: $1.98
Upside: +94.44%
Apr 8, 2026
Maintained: Buy
Price Target: $916 → $921
Current: $852.03
Upside: +8.09%
Mar 25, 2026
Maintained: Hold
Price Target: $20
Current: $23.21
Upside: -13.83%
Mar 20, 2026
Initiated Coverage: Hold
Price Target: $28
Current: $39.49
Upside: -29.10%
Mar 20, 2026
Initiated Coverage: Buy
Price Target: $35
Current: $34.18
Upside: +2.40%
Feb 6, 2026
Maintained: Hold
Price Target: $157 → $201
Current: $222.67
Upside: -9.73%
Jan 13, 2026
Maintained: Hold
Price Target: $65 → $89
Current: $61.33
Upside: +45.12%
Nov 6, 2025
Downgraded: Hold
Price Target: $34 → $9
Current: $15.69
Upside: -42.64%